Supplementary Online Content

Reibaldi M, Fallico M, Avitabile T, et al. Risk of Death Associated With Intravitreal Anti–Vascular Endothelial Growth Factor Therapy: A Systematic Review and Meta-analysis. *JAMA Ophthalmol.* Published online November 21, 2019. doi:10.1001/jamaophthalmol.2019.4636

eTable 1. PRISMA Checklist

eTable 2. Search Strategy

eFigure 1. Risk of Bias Graph

eFigure 2. Risk of Bias Summary

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. PRISMA Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			1
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			3-4
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3-4
INTRODUCTION			5-6
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6
METHODS			6-8
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	-
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6-7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	8

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: **www.prisma-statement.org**.

eTable 2. Search Strategy

Relevant text of randomized clinical trial	Relevant text of diabetic macular oedema
1. Randomized clinical trial	22. Macular edema
2. Randomized controlled trial	23. Macular oedema
3. Randomized	24. 22 or 23
4. Trial	25. Diabetic
5. Groups	26. Diabetes
6. Randomly	27. 25 or 26
7. Drug therapy	28. 24 and 27
8. Placebo	**Relevant text of age-related macular degeneration**
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8	29. Age related macular degeneration
Relevant text of drugs	30. exp macular degeneration/
10. Anti	31. exp choroidal neovascularization/
11. Vascular endothelial growth factor	32. exp retinal degeneration/
12. VEGF	33. exp. retinal neovascularization/
13. 10 and 11, or 10 and 12	34. AMD or ARM or CNV
14. Bevacizumab	35. Maculopathy
15. Ranibizumab	36. 29 or 30 or 31 or 32 or 33 or 34 or 35
16. Aflibercept	**Combined (Final strategy)**
17. Pegaptanib	37. 9 and 18 and 21
18. 13 or 14 or 15 or 16 or 17	38. 9 and 18 and 28
Relevant test for retinal vein occlusion	39. 9 and 18 and 36
19. Retinal vein occlusion	
20. RVO	
21. 19 or 20	

Footnote.Web sites and uniform resource locator: **PubMed**: http://www.ncbi.nlm.nih.gov/pubmed; **Cochrane:** http://www.cochranelibrary.com; **Medline**: http://www.ovid.com/site/catalog/databases/901.jsp;

Embase: http://www.embase.com

eFigure 1. Risk of Bias Graph

eFigure 2. Risk of Bias Summary